Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...

Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Septerna (SEPN), which is developing a treatment for hypoparathyroidism, has proposed terms for an upsized $175M initial ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is ...

Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, ...

(Reuters) -Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its ...

Septerna Inc. shares soared as much as 42% in their trading debut after the biotechnology company raised $288 million in an ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...